



# Low Postseroconversion CD4<sup>+</sup> T-cell Level Is Associated with Faster Disease Progression and Higher Viral Evolutionary Rate in HIV-2 Infection

Angelica A. Palm,<sup>a</sup> Philippe Lemey,<sup>b</sup> Marianne Jansson,<sup>a</sup> Fredrik Månsson,<sup>c</sup> Anders Kvist,<sup>d</sup> Zsófia Szojka,<sup>e</sup> Antonio Biague,<sup>f</sup> Zacarias José da Silva,<sup>f</sup> Sarah L. Rowland-Jones,<sup>g</sup> Hans Norrgren,<sup>d</sup> Joakim Esbjörnsson,<sup>a,g</sup>  Patrik Medstrand,<sup>c</sup> for the SWEGUB CORE Group<sup>‡</sup>

<sup>a</sup>Department of Laboratory Medicine, Lund University, Lund, Sweden

<sup>b</sup>Department of Microbiology and Immunology, Rega Institute, KU Leuven—University of Leuven, Leuven, Belgium

<sup>c</sup>Department of Translational Medicine, Lund University, Lund, Sweden

<sup>d</sup>Department of Clinical Sciences Lund, Lund University, Lund, Sweden

<sup>e</sup>Department of Biochemistry and Molecular Biology, University of Debrecen, Debrecen, Hungary

<sup>f</sup>National Public Health Laboratory, Bissau, Guinea-Bissau

<sup>g</sup>Nuffield Department of Medicine, NDM Research Building, University of Oxford, Oxford, United Kingdom

**ABSTRACT** A positive correlation between virus evolutionary rate and disease progression has been shown for human immunodeficiency virus type 1 (HIV-1) infection. Much less is known about HIV-2, the second causative agent of AIDS. We analyzed 528 HIV-2 *env* V1-C3 sequences generated from longitudinal plasma samples that were collected from 16 study participants during a median observation time of 7.9 years (interquartile range [IQR], 5.2 to 14.0 years). Study participants were classified as faster or slower disease progressors based on longitudinal CD4<sup>+</sup> T-cell data. The HIV-2 evolutionary rate was significantly associated with CD4<sup>+</sup> T-cell levels and was almost twice as high among the faster progressors as among the slower progressors. Higher evolutionary rates were accounted for by both synonymous and nonsynonymous nucleotide substitutions. Moreover, slow disease progression was associated with stronger positive selection on HIV-2/SIVsm (simian immunodeficiency virus infecting sooty mangabey) surface-exposed conserved residues. This study demonstrated a number of previously unknown characteristics linking HIV-2 disease progression with virus evolution. Some of these findings distinguish HIV-2 from HIV-1 and may contribute to the understanding of differences in pathogenesis.

**IMPORTANCE** The relationship between HIV evolution and disease progression is fundamental to our understanding of HIV immune control and vaccine design. There are no clear definitions for faster and slower HIV-2 disease progression and for the relationship of the rate of progression with HIV-2 evolution. To address the hypothesis that viral evolution is correlated with disease progression in HIV-2 infection, we determined faster and slower disease progression based on follow-up data from a prospective cohort of police officers in Guinea-Bissau. The analysis showed that although the CD4<sup>+</sup> T-cell level and the decline in the level were independently associated with progression to AIDS, only the CD4<sup>+</sup> T-cell level or a combined CD4<sup>+</sup> T-cell level/decline stratification was associated with the rate of HIV-2 evolution. The HIV-2 evolutionary rate was almost twice as high among the faster progressors as among the slower progressors. Importantly, this report defines previously unknown characteristics linking HIV-2 disease progression with virus evolution.

**KEYWORDS** disease progression, human immunodeficiency virus, viral evolution

**Citation** Palm AA, Lemey P, Jansson M, Månsson F, Kvist A, Szojka Z, Biague A, da Silva ZJ, Rowland-Jones SL, Norrgren H, Esbjörnsson J, Medstrand P, for the SWEGUB CORE Group. 2019. Low postseroconversion CD4<sup>+</sup> T-cell level is associated with faster disease progression and higher viral evolutionary rate in HIV-2 infection. *mBio* 10:e01245-18. <https://doi.org/10.1128/mBio.01245-18>.

**Editor** Dimitrios Paraskevis, Medical School, University of Athens

**Copyright** © 2019 Palm et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Patrik Medstrand, [patrik.medstrand@med.lu.se](mailto:patrik.medstrand@med.lu.se).

J.E. and P.M. contributed equally to this article.

‡ The members of the SWEGUB CORE (Sweden and Guinea-Bissau Collaboration Research) group are listed in Acknowledgements.

**Received** 5 June 2018

**Accepted** 27 November 2018

**Published** 8 January 2019

It has been estimated that one million to two million people worldwide are infected with HIV-2 (1). Similarly to HIV-1, HIV-2 causes AIDS, but with lower rates of transmission, CD4<sup>+</sup> T-cell decline, and disease progression (2). Despite similar levels of integrated viral DNA (proviral DNA), the plasma viral RNA burden (viral load) at comparable CD4<sup>+</sup> T-cell counts is significantly lower in HIV-2 infections than in HIV-1 infections, suggesting either that HIV-2 is associated with a lower rate of replication or that HIV-2 is more susceptible to immune control (2–8). However, despite the lower level of chronic immune activation in HIV-2 infection, both viruses elicit several immune responses that may modulate disease progression, e.g., neutralizing antibodies and cytotoxic T lymphocytes (2).


The natural history of HIV-2 infection was not known in detail until recently, and cohort data often lack information on the estimated time of HIV-2 infection, precluding assessment of the true rates of HIV-2 disease progression and of the dynamics of CD4<sup>+</sup> T-cell change and plasma viral load during infection (9, 10). In a recent study, we showed that most individuals infected by HIV-2 progress to disease but at a lower rate than for HIV-1 (11). Moreover, the role of CD4<sup>+</sup> T-cell dynamics in HIV-2 infection was shown to be a strong clinical predictor of disease progression. Thus, both HIV-1 disease progression and HIV-2 disease progression are associated with CD4<sup>+</sup> T-cell decline and early initial postseroconversion CD4<sup>+</sup> T-cell levels (11–15).

Both HIV-1 and HIV-2 evolve rapidly due to high mutation rates, high replication rates, and fast generation times (16). This results in extensive genetic variability both within and between infected individuals. The association between viral evolutionary rate (5, 17) and disease progression has been studied extensively for HIV-1, and most studies have suggested that these parameters are positively correlated (18). Much less is known about HIV-2 inpatient evolution; whereas some researchers have reported that HIV-2 has a lower evolutionary rate than HIV-1, others have reported the opposite (5, 17, 19–21). However, no correlation has been found between the virus evolutionary rate and variations in levels of CD4<sup>+</sup> T-cells over time in HIV-2 infection (5, 20). Importantly, those studies were performed on proviral DNA or on RNA obtained from virus propagated in culture, which may not reflect the circulating virus populations. To the best of our knowledge, differences in HIV-2 evolutionary rates between groups with different rates of disease progression have not been investigated.

Here, we aimed to determine whether faster disease progression and slower disease progression are differentiated by rates of decline of and levels of CD4<sup>+</sup> T cells in HIV-2 infection, similarly to what has been previously suggested to be the case in HIV-1 infection (12, 14), and investigated the association between the disease progression rate and the evolutionary dynamics of HIV-2.

## RESULTS

**Study population.** The HIV-2 *env* V1-C3 region was successfully reverse transcribed and amplified from 53 plasma samples that had been collected longitudinally from 16 study participants of a well-described cohort of police officers in Guinea-Bissau (22, 23). Inclusion criteria and clinical characteristics are presented in Materials and Methods (see also Table S1 and S2 at [https://dochub.com/patrik-medstrand/zqp8z8/supplementaryinformation\\_palm\\_mbio\\_ver2\\_180822?dt=Nx2HKD\\_\\_sa\\_SKWC-XzVE](https://dochub.com/patrik-medstrand/zqp8z8/supplementaryinformation_palm_mbio_ver2_180822?dt=Nx2HKD__sa_SKWC-XzVE)). The median observation time from inclusion until the last registered visit for the 16 included individuals was 19.2 years (interquartile range [IQR], 15.0 to 20.8 years). A median of seven clones from each time point were sequenced, and the median time between the collection dates of the first and last amplified patient-specific samples was 7.9 years (IQR, 5.2 to 14.0 years). Among the 528 sequences, 119 putative recombinant sequences were removed, leaving 409 sequences for evolutionary analyses. Phylogenetic subtype analysis showed that all sequences belonged to HIV-2 group A. Moreover, all sequences from each individual formed distinctive monophyletic clades in the phylogeny, indicating that sequences from the study participants were not subjected to superinfection, coinfection, mix-up during sample handling, or con-



**FIG 1** Kaplan-Meier curves of AIDS-free time. Three stratifications were explored (fast and slow progressors were defined by having values above or below the mean values from all participants for each stratification). (A) CD4% decline rate. (B) CD4% level at the midpoint in time between the first and last recorded CD4% values. (C) Combined effect of CD4% decline rate and CD4% level. Tick marks indicate participants with censored data. Asterisks indicate the time points in each group when five participants were still at mortality risk and at risk of developing AIDS. The numbers of individuals at risk are given below the figure panels at 5-year intervals. Data from faster progressors are shown in vermilion, and data from slower progressors are shown in blue.

tamination during the laboratory procedures (see Fig. S1 at [https://dochub.com/patrik-medstrand/zqp8z8/supplementaryinformation\\_palm\\_mbio\\_ver2\\_180822?dt=Nx2HKD\\_\\_sa\\_SKWC-XzVE](https://dochub.com/patrik-medstrand/zqp8z8/supplementaryinformation_palm_mbio_ver2_180822?dt=Nx2HKD__sa_SKWC-XzVE)).

**Classification of individuals as faster and slower progressors based on longitudinal CD4<sup>+</sup> T-cell dynamics.** To assess the link between HIV-2 evolutionary estimates and disease progression, we classified the study participants into groups of faster disease progressors and slower disease progressors based on longitudinal CD4<sup>+</sup> T-cell dynamics from the entire HIV-2-infected population of the Guinea-Bissau police cohort. To determine if faster disease progression can be differentiated from slower disease progression by CD4<sup>+</sup> T-cell decline and level in cases of HIV-2 infection also, as had been previously suggested for HIV-1 infection (12, 14), we analyzed the time to the appearance of AIDS from the first recorded percentages of CD4 (CD4%) for all HIV-2-infected individuals in the cohort with two or more CD4% measurements ( $n = 192$ ). Three stratifications were used, and faster and slower progressors were defined as those patients whose CD4% values were above and below the mean of the values determined for all participants for each stratification, respectively (Fig. 1). The first stratification, referred to as the CD4% decline rate, was based on individual coefficients of regression for CD4%. Eighty-one participants were classified as faster progressors (mean CD4% decline, 2.7% per year [standard deviation {SD}, 2.6]) and 111 as slower progressors (mean CD4% increase, 0.5% per year [SD, 1.6]). The median time to AIDS from the first recorded CD4% value was 11.7 years (95% confidence interval [CI], 7.3 to 16.1 years) for faster progressors with a faster CD4% decline and 16.8 years (CI, 12.3 to 21.3 years) for slower progressors with a slower CD4% decline ( $P = 0.008$  [log rank test]) (Fig. 1A). The second stratification, referred to here as the CD4% level, was determined as the CD4% level at the midpoint in time between the first and last recorded CD4% levels using the regression line generated in the first stratification. Eighty-seven participants were classified as faster progressors (mean CD4% level, 21.0% [SD, 4.3%]) and 105 as slower progressors (mean CD4% level, 35.0% [SD, 5.7%]). The median time to AIDS from the first recorded CD4% value was 9.4 years (95% CI, 6.7 to 12.1 years) for faster progressors with a low CD4% level and 15.5 years (95% CI, 14.3 to 16.6 years) in slower progressors with a high CD4% level ( $P < 0.001$  [log rank test]) (Fig. 1B). In the third stratification, referred to as the combined coefficient, the CD4% decline rate and CD4% level were combined to have equal influences on the stratification (see Materials and Methods). Eighty-five participants were classified as faster progressors (combined coeffi-

**TABLE 1** Disease progression classifications of all individuals, based on three different stratifications for CD4% ( $n = 16$ )

Individual	CD4% decline rate/year		CD4% level		Combined coefficient	
	Value <sup>a</sup>	Progressor <sup>b</sup>	Value <sup>a</sup>	Progressor <sup>b</sup>	Value <sup>a,c</sup>	Progressor <sup>b</sup>
DL3405	-1.46	Slow	33.95	Slow	1.00	Slow
DL3542	0.69	Fast	32.73	Slow	0.74	Slow
DL2051	1.61	Fast	31.11	Slow	0.62	Slow
DL2876	0.55	Fast	28.91	Slow	0.67	Slow
DL3654	-0.15	Slow	27.74	Slow	0.70	Slow
DL2533	-1.10	Slow	23.96	Slow	0.68	Slow
DL2316	1.10	Fast	23.45	Fast	0.50	Fast
DL2794	-0.11	Slow	20.99	Fast	0.53	Fast
DL3941	3.40	Fast	20.65	Fast	0.29	Fast
DL2381	1.17	Fast	20.62	Fast	0.44	Fast
DL2335	0.58	Fast	20.41	Fast	0.47	Fast
DL3647	0.73	Fast	19.63	Fast	0.44	Fast
DL3646	0.33	Slow	19.32	Fast	0.46	Fast
DL3222	-0.88	Slow	19.25	Fast	0.53	Fast
DL3740	-0.69	Slow	17.57	Fast	0.48	Fast
DL2386	1.61	Fast	16.29	Fast	0.32	Fast

<sup>a</sup>Data represent individual values for the three different stratifications.

<sup>b</sup>Individuals with values above or below the mean values determined for all individuals were grouped as faster or slower progressors, respectively.

<sup>c</sup>The combined coefficient values represent a combination of CD4% decline rate and CD4% level. The combined coefficient values were obtained by transforming the CD4% decline rate values and CD4% level values, setting them to comparable scales, and subsequently multiplying them.

cient below the mean) and 107 as slower progressors (combined coefficient above the mean). The median time to AIDS from the first recorded CD4% value was 8.6 years (95% CI, 6.5 to 10.8 years) for faster progressors with a low combined coefficient and 18.7 years (95% CI, 13.6 to 23.8 years) for slower progressors with a high combined coefficient ( $P < 0.001$  [log rank test]) (Fig. 1C). Interestingly, only 50% of the participants were consistently classified as faster or slower progressors in the stratifications (see Table S3 at [https://dochub.com/patrik-medstrand/zqp8z8/supplementaryinformation\\_palm\\_mbio\\_ver2\\_180822?dt=Nx2HKD\\_sa\\_SKWC-XzVE](https://dochub.com/patrik-medstrand/zqp8z8/supplementaryinformation_palm_mbio_ver2_180822?dt=Nx2HKD_sa_SKWC-XzVE)). A Cox proportional-hazards model with CD4% decline and level as discrete covariates (according to the stratifications described above) showed that CD4% decline and level were independently associated with disease progression rate ( $P = 0.007$  for CD4% decline and  $P < 0.001$  for CD4% level [Wald test]; the independence of these covariates was determined by a nonsignificant interaction term between the covariates corresponding to  $P = 0.85$  [Wald test]).

**The HIV-2 evolutionary rate is associated with CD4% level and combined coefficient but not with CD4% decline alone.** Since all three stratifications described above were significantly linked to the rate of disease progression, we decided to assess differences in virus evolutionary parameters for all three stratifications (Table 1). Model evaluation within the hierarchical phylogenetic modeling (HPM) framework indicated that a strict clock with a constant size demographic model generally fitted our data best for both the nucleotide and codon models (see Materials and Methods and Text S1 at [https://dochub.com/patrik-medstrand/zqp8z8/supplementaryinformation\\_palm\\_mbio\\_ver2\\_180822?dt=Nx2HKD\\_sa\\_SKWC-XzVE](https://dochub.com/patrik-medstrand/zqp8z8/supplementaryinformation_palm_mbio_ver2_180822?dt=Nx2HKD_sa_SKWC-XzVE) for details). The overall mean evolutionary rate of the V1-C3 region was  $23.5 \times 10^{-3}$  codon substitutions/site/year (95% highest posterior density [HPD] interval,  $20.3 \times 10^{-3}$  to  $26.6 \times 10^{-3}$ ) (Table 2). No association was found between evolutionary rate and disease progression when individuals were classified as faster or slower progressors based on CD4% decline rate (Bayes factor [BF] = 0.3) (Table 2). In contrast, when individuals were classified based on either CD4% level or the combined coefficient, the mean evolutionary rate was significantly higher in faster progressors ( $28.6 \times 10^{-3}$  codon substitutions/site/year; 95% HPD,  $24.2 \times 10^{-3}$  to  $33.5 \times 10^{-3}$ ) than in slower progressors ( $14.9 \times 10^{-3}$  codon substitutions/site/year; 95% HPD,  $12.2 \times 10^{-3}$  to  $17.6 \times 10^{-3}$ ) (BF = 20.3) (Table 2). Similar differences were

**TABLE 2** Evolutionary rates ( $10^{-3}$  codon substitutions/site/year) in the V1-C3 *env* regions determined using a strict clock hierarchical phylogenetic model<sup>a</sup>

Genetic region	All individuals <sup>c</sup>	CD4% stratification					
		CD4% decline rate			CD4% level and the combined coefficient <sup>b</sup>		
		Fast progressors <sup>c</sup>	Slow progressors <sup>c</sup>	Bayes factor <sup>d</sup>	Fast progressors <sup>c</sup>	Slow progressors <sup>c</sup>	Bayes factor <sup>d</sup>
V1-C3	23.5 (20.3-26.6)	24.7 (20.1-29.6)	21.9 (19.1-24.9)	0.3	28.6 (24.2-33.5)	14.9 (12.2-17.6)	20.3
V1V2	29.5 (25.1-34.2) <sup>a</sup>	30.1 (24.6-36.0)	28.8 (23.7-34.0)	0.3	35.4 (28.9-42.2)	19.6 (14.8-24.7)	11.8
C2	18.0 (15.2-20.7) <sup>a</sup>	18.6 (15.3-21.9)	16.7 (13.9-19.5)	0.3	21.5 (17.6-25.7)	12.0 (9.2-15.2)	28.4
V3	21.2 (17.0-25.7) <sup>a</sup>	21.6 (16.5-26.8)	20.8 (15.7-25.9)	0.3	24.1 (18.0-30.6)	16.5 (11.0-22.2)	2.4
C3	26.6 (22.6-31.1) <sup>a</sup>	27.0 (22.0-32.4)	26.0 (21.6-30.6)	0.2	30.4 (24.3-27.0)	20.2 (15.2-25.8)	6.1

<sup>a</sup>*P* values for Wilcoxon signed rank tests for comparisons of rates between regions were as follows: for V1V2 versus C2, <0.001; for V1V2 versus V3, 0.002; for V1V2 versus C3, 1; for C2 versus V3, 0.005; for C2 versus C3, <0.001; for V3 versus C3, <0.001.

<sup>b</sup>The combined coefficient values represent a combination of CD4% decline rate and CD4% level.

<sup>c</sup>Data correspond to  $10^{-3}$  codon substitutions per site per year (95% highest posterior density interval).


<sup>d</sup>Bayes factor (BF) support for association between codon substitution rate and disease progression (faster versus slower progressors). BF >3 was considered evidence of a significant association.

found for the nucleotide substitution rate (BF = 0.3 for association with CD4% decline rate and BF = 17.5 for association with CD4% level or the combined coefficient) (see Table S4 at [https://dochub.com/patrik-medstrand/zqp8z8/supplementaryinformation\\_palm\\_mbio\\_ver2\\_180822?dt=Nx2HKD\\_\\_sa\\_SKWC-XzVE](https://dochub.com/patrik-medstrand/zqp8z8/supplementaryinformation_palm_mbio_ver2_180822?dt=Nx2HKD__sa_SKWC-XzVE)).

**Higher evolutionary rate in the HIV-2 V1V2 and C3 region than in the C2 and V3 region.** To determine if the evolutionary rates were similar in different regions of *env*, we partitioned the data set into four well-defined regions: V1V2, C2, V3, and C3. The evolutionary rate was higher in both the V1V2 and C3 regions than in the C2 and V3 regions, respectively (Table 2) ( $P < 0.05$  [Wilcoxon signed rank test with Bonferroni correction for all pairwise comparisons]). No significant difference was found between faster and slower progressors in any of the four V1-C3 regions when individuals were stratified by CD4% decline rate (BF values ranged from 0.2 to 0.3). In contrast, moderate to strong associations between evolutionary rate and disease progression were found in the V1V2 (BF = 11.8), C2 (BF = 28.4), and C3 (BF = 6.1) regions for individuals grouped according to CD4% level or the combined coefficient. A weak association was also noted in the V3 region (BF = 2.4).

Since the CD4% level and the combined coefficient stratifications resulted in identical groupings (Table 1) and all analyses indicated a strong association between evolutionary rate and CD4% level—in contrast to the absence of associations between evolutionary rate and CD4% decline rate—only results based on the CD4% level stratification are presented for the subsequent analyses.

**V1-C3 of HIV-2 *env* evolves under conditions of negative selection.** Next, we hypothesized that the differences in evolutionary rate between the progressor groups could have originated in parameters influencing selection pressure or viral replication. We therefore estimated the ratio of nonsynonymous substitution rates to synonymous substitution rates (the dN/dS rate ratio), which indicates whether a gene or site had been subjected to positive selection (dN/dS > 1) or to negative selection (dN/dS < 1) or had evolved neutrally (dN/dS = 1). We found global negative selection over the entire V1-C3 region (dN/dS rate ratio = 0.56; 95% HPD interval, 0.49 to 0.63), with no statistical differences apparent between faster and slower progressors (BF = 1.3) (see Table S5 at [https://dochub.com/patrik-medstrand/zqp8z8/supplementaryinformation\\_palm\\_mbio\\_ver2\\_180822?dt=Nx2HKD\\_\\_sa\\_SKWC-XzVE](https://dochub.com/patrik-medstrand/zqp8z8/supplementaryinformation_palm_mbio_ver2_180822?dt=Nx2HKD__sa_SKWC-XzVE)). The region-specific analyses showed that the V1V2 and C3 regions evolved neutrally (dN/dS rate ratios, 1.27 [95% HPD interval, 0.84 to 1.80] and 0.94 [95% HPD interval, 0.70 to 1.22], respectively) whereas the C2 and V3 regions had been subjected to strong negative selection (dN/dS rate ratios, 0.22 [95% HPD interval, 0.18 to 0.27] and 0.41 [95% HPD interval, 0.27 to 0.57], respectively). No significant differences were found in dN/dS rate ratios between the progressor groups in the V1V2, V3, or C3 regions (BF values of <3 for all regions), whereas a moderately higher level of negative selection was found in the C2 region among faster




**FIG 2** Synonymous and nonsynonymous divergence over time. Data represent accumulated synonymous and nonsynonymous divergences over time in the V1-C3 *env* region of HIV-2 for each study participant. The divergence from the level seen with the first analyzed sample from each study participant is shown. Data from faster progressors are shown in vermilion, and data from slower progressors are shown in blue.

progressors than among the slower progressors (BF = 3.7) (see Table S5 at [https://dochub.com/patrik-medstrand/zqp8z8/supplementaryinformation\\_palm\\_mbio\\_ver2\\_180822?dt=Nx2HKD\\_\\_sa\\_SKWC-XzVE](https://dochub.com/patrik-medstrand/zqp8z8/supplementaryinformation_palm_mbio_ver2_180822?dt=Nx2HKD__sa_SKWC-XzVE)).

**Higher nonsynonymous and synonymous substitution rates in faster progressors than in slower progressors.** Whereas the dN/dS rate ratio provides an estimate of the overall selective pressure, analyses of expected nonsynonymous (E[N]) and expected synonymous (E[S]) substitution rates can add detailed information concerning replication and selection pressure (17). The E[N] and E[S] divergences were estimated and plotted as accumulated divergence rates over time from the first analyzed sample (Fig. 2; see also Table S6 at [https://dochub.com/patrik-medstrand/zqp8z8/supplementaryinformation\\_palm\\_mbio\\_ver2\\_180822?dt=Nx2HKD\\_\\_sa\\_SKWC-XzVE](https://dochub.com/patrik-medstrand/zqp8z8/supplementaryinformation_palm_mbio_ver2_180822?dt=Nx2HKD__sa_SKWC-XzVE)). The HIV-2 divergence rates increased in a relatively linear manner during the asymptomatic phase of infection, and viral populations in faster progressors accumulated both nonsynonymous and synonymous substitutions faster than those in slower progressors. The median E[N] rate ranged from  $3.0 \times 10^{-3}$  to  $6.6 \times 10^{-3}$  nucleotide [nt] substitutions/site/year for faster progressors and from  $1.4 \times 10^{-3}$  to  $4.6 \times 10^{-3}$  nt substitutions/site/year for slower progressors ( $P = 0.005$  [two-tailed Mann-Whitney U test [M-W]]). The median E[S] rate ranged from  $4.5 \times 10^{-3}$  to  $11.2 \times 10^{-3}$  nt substitutions/site/year for faster progressors and from  $1.1 \times 10^{-3}$  to  $4.0 \times 10^{-3}$  nt substitutions/site/year for slower progressors ( $P < 0.001$  [M-W]). These results are in line with the higher overall viral evolutionary rates for faster progressors than for slower progressors seen in the HPM analyses and clarify why no statistically significant differences were found in dN/dS rate ratios.

**Higher number of conserved sites under conditions of positive selection in slower HIV-2 disease progression.** Although the analysis described above indicated the presence of general negative selection across the entire V1-C3 region, we hypothesized that a number of specific residues could have been subject to positive selection. To assess this hypothesis, we used a Renaissance counting procedure to estimate the dN/dS rate ratio at each codon site (Fig. 3). Only a low proportion of sites showed signatures of positive selection, and the proportions of positively selected sites were not significantly different between the viral populations of faster and slower progressors across the V1-C3 region (7% and 11%, respectively;  $P = 0.503$  [M-W]) or in the V1-C3 regions in separate analyses (see Table S7 at [https://dochub.com/patrik-medstrand/zqp8z8/supplementaryinformation\\_palm\\_mbio\\_ver2\\_180822?dt=Nx2HKD\\_\\_sa\\_SKWC-XzVE](https://dochub.com/patrik-medstrand/zqp8z8/supplementaryinformation_palm_mbio_ver2_180822?dt=Nx2HKD__sa_SKWC-XzVE)). While the numbers of sites under positive selection were similar in the faster and slower progressors in the V1V2, V3, and C3 regions, slower progressors



**FIG 3** Codon-specific selective pressure. The selective pressures at each codon site of the sequence alignment of the *env* V1-C3 region of HIV-2 for faster and slower disease progressors are indicated. The proportions (y axis) with positive selection (vermillion or blue) or negative selection (gray) at codon sites of the sequence alignment (x axis) are shown for faster progressors (upper graph) and slower progressors (lower graph). Filled black circles indicate codons conserved between HIV-2/SIVsm strains associated with positive selection. Vertical lines divide the fragment into *env* regions V1V2, C2, V3, and C3.

had more sites under positive selection in the C2 region than faster progressors (35 versus 20 sites) ( $P = 0.026$  [two-tailed Fisher's exact test {FET}]) (Fig. 3). Since it has been shown that the HIV-2 C2 and C3 regions are exposed similarly to the corresponding HIV-1 regions and are under negative selection, we hypothesized that the effects of positive selection on amino acids subjected to structural and functional constraints would negatively impact viral fitness (24). We therefore defined the amino acids critical to viral fitness as those amino acids that were conserved between HIV-2 and the simian immunodeficiency virus (SIV) from which HIV-2 originated through cross-species transmission (i.e., SIVsm, the SIV infecting sooty mangabeys [*Cercocebus atys*]) and compared the ratios of positive selection of viral lineages between slower and faster progressors (25). Among the 246 amino acids in the V1-C3 regions, 84 were conserved between SIVsm and HIV-2 (see Table S8 at [https://dochub.com/patrik-medstrand/zqp8z8/supplementaryinformation\\_palm\\_mbio\\_ver2\\_180822?dt=Nx2HKD\\_\\_sa\\_SKWC-XzVE](https://dochub.com/patrik-medstrand/zqp8z8/supplementaryinformation_palm_mbio_ver2_180822?dt=Nx2HKD__sa_SKWC-XzVE)). Comparisons of the numbers of conserved HIV-2/SIVsm sites under positive selection showed that slower progressors had more conserved sites under positive selection than faster progressors (20 versus 5 sites ( $P = 0.002$  [FET])) in the V1-C3 region. The differences between the slower and faster progressors with respect to positive selection at conserved sites were most highly pronounced in the C2 region (12 versus 3 sites, respectively) ( $P = 0.021$  [FET]), while such differences were not observed in the V1V2, V3, and C3 regions. To confirm previous observations that C2 is well exposed on the HIV-2 *env* gene, we used the published structural data of HIV-2 gp125 to visualize the amino acids in the V1-C3 region (24, 26). This analysis indicated that the majority (15 of 22) amino acids associated with positive selection mapped to exposed surfaces on HIV-2 gp125 (see Fig. S2 at [https://dochub.com/patrik-medstrand/zqp8z8/supplementaryinformation\\_palm\\_mbio\\_ver2\\_180822?dt=Nx2HKD\\_\\_sa\\_SKWC-XzVE](https://dochub.com/patrik-medstrand/zqp8z8/supplementaryinformation_palm_mbio_ver2_180822?dt=Nx2HKD__sa_SKWC-XzVE)). Moreover, the surface accessibility of amino acids within the V1-C3 regions showed that the

positively selected sites were associated with residues with solvent-exposed surfaces in the C2 region (29 of 68 amino acids) ( $P = 0.040$  [FET]).

## DISCUSSION

The relationship between HIV evolution and disease progression is fundamental to our understanding of HIV immune control and vaccine design. We recently showed an association between CD4<sup>+</sup> T-cell decline/CD4<sup>+</sup> T-cell level and HIV-2 disease progression rate (11). Here we defined relatively faster and slower HIV-2 disease progression using these associations and dissected the associations between HIV-2 evolutionary dynamics and disease progression. Studies addressing these associations for HIV-2 infection have been limited (5, 17, 20, 27). In HIV-2 infection, disease in many patients progresses slowly, but in some the advance is as fast as that in HIV-1 infection (28–30). The reasons for this marked heterogeneity are currently not known, but mechanisms similar to those of HIV-1 infection may be involved (11, 31). To address the hypothesis that viral evolution is associated with disease progression in HIV-2 infection also, we first determined stratifications for relatively faster and slower disease progression based on follow-up data from the entire prospective cohort of police officers in Guinea-Bissau. The analysis showed that although CD4<sup>+</sup> T-cell level and decline were independently associated with progression to AIDS, the effect size was largest for the CD4% level or the combined CD4% level/decline stratifications. This observation is in line with previous reports showing that the CD4<sup>+</sup> T-cell level at corresponding time points after infection may be a better marker for both HIV-1 and HIV-2 disease progression rates than CD4<sup>+</sup> T-cell decline (11, 12, 14). Moreover, only the CD4<sup>+</sup> T-cell level or the combined CD4<sup>+</sup> T-cell level/decline stratifications were associated with the evolutionary rate of HIV-2. This observation suggests that the postseroconversion CD4<sup>+</sup> T-cell level is associated with the rate of disease progression (32), whereas the rate of CD4<sup>+</sup> T-cell decline during chronic infection can be viewed as an additive component influencing progression in combination with the initial CD4<sup>+</sup> T-cell levels. The reasons for and mechanisms that determine the variability of CD4<sup>+</sup> T-cell decline range from genetic and biological factors to physiological factors (33, 34). In those with a low postseroconversion level of CD4 cells, progression to AIDS is faster (and the time to AIDS shorter) than among those with a higher postseroconversion level of CD4 cells (11). It is possible that events that occur during acute infection dictate the initial postseroconversion levels of CD4 T-positive (T<sup>+</sup>) cells in HIV-2 infection also (11, 32). Thus, a broader assessment of disease progression may provide additional understanding of the mechanisms that drive the disease pathogenesis.

Many HIV-2-infected individuals remain nonprogressors with low viral loads during the course of infection, and HIV-2 sequences can be obtained only from individuals with detectable plasma viral loads (35). Hence, HIV-2-infected individuals without detectable viremia cannot be assessed in studies of HIV-2 evolution in plasma. However, our assay had a detection limit of 12 RNA copies/ml plasma, indicating that even slow progressors with low viral loads (<50 copies/ml plasma) could be detected.

A strong association between HIV-2 evolutionary rate and disease progression was found in all the studied genetic subregions, except for V3. For HIV-1, the flanking V3 region is known to be highly exposed and immunodominant (36). By contrast, the V3 region of HIV-2 has been suggested to be more highly concealed from the immune system and to be the least entropic and positively selected part of the C2-C3 region (24). Our findings of lower evolutionary rates and stronger purifying selection in the C2 and V3 regions support previous suggestions that the immune response of HIV-2-infected individuals may be more highly directed to other regions of the HIV-2 envelope (27, 37, 38).

Our HIV-2 evolutionary rate estimates are in the range of what has been reported by others, although direct comparisons are difficult due to differences in the *env* regions analyzed and to the use of different phylogenetic models (17, 20, 21). In a previous study of HIV-1 subtype B based on a similar methodological approach, the evolutionary rate of the HIV-1 V1-V3 region was estimated to be approximately twice as high as our

estimates for HIV-2 (39). The uncertainty of how the HIV-2 evolutionary rate compares with the rate of HIV-1 highlights the need for a direct comparison of HIV-1 evolution to HIV-2 evolution in the same population using the same approaches. Previous studies of HIV-2 intrahost evolution have been based on limited numbers of individuals and time points. The generally low viral loads among HIV-2-infected individuals continue to present a large technical challenge and are likely to have contributed to the paucity of intrahost HIV-2 evolutionary studies (6–8).

In a stratified analysis, we found that both nonsynonymous and synonymous substitutions accumulated at a higher rate in faster progressors than in slower progressors. This result suggests generally faster replication rates and shorter generation times for virus populations in faster progressors and is in line with previous reports of increased virus replication rates among immunosuppressed individuals infected with HIV-2 (40). It is possible that increased replication rates can reduce the generation time in intrahost virus populations and can lead to higher rates of neutral evolution. This has also been suggested to explain the association between disease progression and synonymous substitution rates in HIV-1 infection (17, 41).

Previous studies have demonstrated that the *env* gene is under purifying selective pressure overall in both HIV-1 and HIV-2 infection, with a few irregularly distributed positively selected sites (42, 43). Comparisons between HIV-1 disease progressor groups have suggested that slow-disease progressors are associated with a higher number of positively selected sites (44). Similarly to HIV-1 data, we identified a few positively selected sites in the majority of HIV-2 slow progressors. However, the mean dN/dS rate ratios and the proportions of positively selected sites did not differ between slower and faster progressors. Instead, we found that slow HIV-2 disease progression was associated with a higher level of positive selection on a selected number of surface-exposed residues conserved between HIV-2/SIVsm. It is tempting to speculate that slow progressors may elicit a stronger immune response to highly surface-exposed conserved residues, which may in turn impact viral fitness, since such conserved amino acids are likely to have a functional and structural impact on envelope functions (24, 27, 45). If true, our findings would be consistent with the concept that hosts who mount a stronger immune response against the infecting virus have greater numbers of positively selected sites and progress to AIDS at a lower rate, which is reflected by higher postseroconversion CD4<sup>+</sup> T-cell levels (44). In line with this, Bohl et al. showed that mutations of conserved residues of HIV-2 envelope resulted in poor envelope function (46).

In conclusion, our analyses show a strong association between HIV-2 evolutionary rate and disease progression as determined by CD4% levels. Overall negative selection was demonstrated in the analyzed HIV-2 *env* fragment, with the proportion of positively selected sites in the range of what has been shown for HIV-1. Interestingly, slow disease progression among HIV-2-infected individuals was associated with higher levels of positive selection on residues conserved between HIV-2 and SIVsm, which may indicate generally reduced viral fitness among these viral variants. Our findings provide new insights into the associations between pathogenesis and intrahost evolution of HIV-2. Still, more studies on how the dynamics of disease progression rate is shaped by the molecular evolution of HIV-2 are warranted. Further knowledge of HIV-2 pathogenesis and comparisons between HIV-1 and HIV-2 will be important to reveal fundamental differences in how these two viruses cause immunodeficiency.

## MATERIALS AND METHODS

**Study population.** This study included individuals from a large cohort of police officers in Guinea-Bissau, West Africa, which was formed in 1990 (22, 23). At inclusion, and at follow-up visits scheduled with an interval of 12 to 18 months, individuals were examined and a plasma sample was collected. The civil war in 1998 to 1999 temporarily (from June 1998 until the end of 2002) ended inclusion, but annual visits of previously included individuals were resumed in July 2000. The cohort was followed routinely until February 2011, when the cohort was closed. In September 2013, however, selected individuals from the cohort were asked to participate in a special sampling round, including a clinical examination and collection of a plasma sample. In early 2006, the police cohort was included in the national antiretroviral therapy (ART) program which was introduced into Guinea-Bissau in 2005. HIV testing was performed at

the National Public Health Laboratory (LNSP), Bissau, as previously described (22). The CD4<sup>+</sup> T-cell count and CD4% were determined at each follow-up visit after infection (14, 22, 23). In the absence of commercial HIV-2 RNA assays, HIV-2-infected patients are generally monitored by CD4<sup>+</sup> T-cell levels, particularly in areas of endemicity. Consequently, viral load measurements have not been included as a standard procedure in Guinea-Bissau, preventing us from a comprehensive analysis of viral load data in this study.

The cohort includes 438 seroincident and seroprevalent HIV-2-infected individuals, 83 of whom had an estimated date of seroconversion, defined as the midpoint between the last HIV-2 seronegative sample collection date and the first seropositive sample collection date. Individuals with long follow-up series, including both CD4% measurements and available plasma samples, were considered for inclusion in the study. Our initial goal was to conduct this study by including only individuals with estimated dates of infection. Thus, amplification of viral RNA was attempted on plasma samples from seroincident individuals from whom three or more longitudinal plasma samples were available ( $n = 19$ ). As expected, due to the generally low viral loads in HIV-2 infections, amplification was successful for only a minority of samples and seven individuals with two or more successfully amplified longitudinal samples could be included in the study. We therefore decided to also include seroprevalent individuals (i.e., individuals who were HIV-2 infected already at enrollment) in the study. Due to the anticipated difficulties in amplifying HIV-2 RNA, only individuals with more than six available plasma samples were considered for inclusion. Amplification was attempted on samples from 19 individuals, and successful amplification of two or more longitudinal samples was achieved for 9 individuals. Taking the data together, amplification was attempted on samples from 38 individuals, where 16 individuals fulfilled the inclusion criterion of the availability of two or more amplified longitudinal samples (total, 53 samples). The majority of the plasma samples were collected from the 16 participants included in this study during the asymptomatic phase of infection, defined by a CD4<sup>+</sup> T-cell count of  $>200$  cells/ $\mu$ l, CD4% of  $>14$ , and a lack of clinical AIDS symptoms (WHO stage 4 and CDC stage C [47, 48]). However, seven samples from six individuals were collected after the individuals had developed AIDS, and two samples from two individuals were collected after the individuals had initiated antiretroviral therapy (see Table S2 at [https://dochub.com/patrik-medstrand/zqp8z8/supplementaryinformation\\_palm\\_mbio\\_ver2\\_180822?dt=Nx2HKD\\_\\_sa\\_SKWC-XzVE](https://dochub.com/patrik-medstrand/zqp8z8/supplementaryinformation_palm_mbio_ver2_180822?dt=Nx2HKD__sa_SKWC-XzVE)). Baseline characteristics of the 16 individuals are presented in Table S1 at [https://dochub.com/patrik-medstrand/zqp8z8/supplementaryinformation\\_palm\\_mbio\\_ver2\\_180822?dt=Nx2HKD\\_\\_sa\\_SKWC-XzVE](https://dochub.com/patrik-medstrand/zqp8z8/supplementaryinformation_palm_mbio_ver2_180822?dt=Nx2HKD__sa_SKWC-XzVE), and successfully amplified samples are listed in Table S2 at [https://dochub.com/patrik-medstrand/zqp8z8/supplementaryinformation\\_palm\\_mbio\\_ver2\\_180822?dt=Nx2HKD\\_\\_sa\\_SKWC-XzVE](https://dochub.com/patrik-medstrand/zqp8z8/supplementaryinformation_palm_mbio_ver2_180822?dt=Nx2HKD__sa_SKWC-XzVE).

The 16 included individuals were subsequently stratified as faster or slower progressors using three different parameters: CD4% decline rate, CD4% level, and a combined coefficient. The combined coefficient was achieved by combining the CD4% decline rate and the CD4% level. Since these values were quantified on different scales and since the CD4% decline rate could be either positive or negative, we transformed the values before combining them. The two variables were transformed and rescaled to have equal levels of influence on the combined coefficient. More specifically, to account for negative CD4% decline rates, all rates were transformed to positive rates with the corresponding relative difference. Next, CD4% decline rates and CD4% levels were rescaled to include the same extrema. Individual combined coefficients were then determined for each study participants by multiplying the rescaled CD4% decline rates and CD4% levels. There were no differences in age between the groups at the time of the first HIV-2-positive sample (data not shown).

**Amplification and sequencing.** Viral RNA was extracted from patient plasma samples using an miRNeasy microkit (Qiagen, Stockholm, Sweden) with minor modifications to the manufacturer's instructions. Briefly, 200  $\mu$ l of plasma was disrupted in 2,000  $\mu$ l QIAzol and loaded onto an RNeasy MinElute Spin column in the presence of 15  $\mu$ g carrier RNA (Qiagen, Stockholm, Sweden). DNA was removed using an on-column DNase treatment (Qiagen, Stockholm, Sweden), and purified RNA was eluted in 22  $\mu$ l RNase-free H<sub>2</sub>O. An approximately 935-bp fragment that included the complete V1-C3 region of *env* (nt 6986 to 7920 in the BEN reference sequence; GenBank accession number [M30502](https://www.ncbi.nlm.nih.gov/nuccore/M30502)) was amplified using 9.5  $\mu$ l eluted RNA in a SuperScript III One-Step reverse transcription-PCR (RT-PCR) system with Platinum *Taq* DNA polymerase followed by a seminested PCR approach using Platinum *Taq* High Fidelity (Invitrogen, Copenhagen, Denmark). Primers KH2\_OF (5'-GAGACATCAATAAAACCATGTGTC-3') and TH2\_OR (5'-TTCTGCCACCTCTGCACTAAAGG-3') were used for One-Step PCR, and primers KH2\_OF and KH2\_OR (5'-ACCCAATTGAGGAACCAAGTCA-3') were used for nested PCR (5, 42). Following the initial cDNA synthesis performed for 30 min at 50°C, the PCR conditions were identical for One-Step PCR and the nested PCR: initial denaturation for 2 min at 94°C; 40 cycles of 15 s at 94°C, 30 s at 50°C, and 1 min at 68°C; and a final elongation step for 5 min at 68°C. The sensitivity of the PCR was found to be 12 RNA copies/ml plasma as determined by a dilution series performed with an electron microscopy-counted HIV-2 particle (Advanced Biotechnologies, Eldersburg, MD, USA). Molecular cloning of the amplified fragments using a pCR2.1 TOPO cloning system (Invitrogen) was performed by BaseClear BV (Leiden, The Netherlands), and 12 individual clones were routinely picked for subsequent sequencing on both strands using conventional M13 primers.

Sequences were manually edited using CodonCode Aligner v1.5.2 (CodonCode Corporation, Dedham, MA, USA) and aligned in MEGA5 using the Clustal algorithm (49). Sequences of poor quality and sequences containing stop codons were removed from the analysis. Parts of the sequence that were difficult to align were removed in full codons to preserve an open reading frame, resulting in a final alignment length of 774 bp. The alignment spanned the last 30 bp in the 3' end of the C1 region, the entire V1-C3 region, and the first 6 bp in the 5' end of the V4 region. To analyze different subregions, the fragment was partitioned as follows: V1V2, bp positions 31 to 201 (positions 7040 to 7318 in the BEN

reference sequence); C2, positions 202 to 498 (7319 to 7615); V3, positions 499 to 600 (7616 to 7717); C3, positions 601 to 768 (7718 to 7891).

**Survival analysis.** Kaplan-Meier analyses were performed for progression time to AIDS. Cases that did not reach AIDS during follow-up were right censored at their last clinical examination date. Statistical comparisons were performed by the log rank test. A Cox proportional-hazards model was applied to determine independency of covariates (as defined by nonsignificant interaction terms between covariates).

**Phylogenetic analysis.** Putative intrapatient recombinant sequences were identified by the pairwise homoplasy index (PHI) test using an exhaustive and iterative search algorithm and were then removed from the data set (50) (the Perl script for the iterative search is available from the authors upon request). Maximum likelihood (ML) phylogenetic trees were reconstructed using the inferred model, GTR +I + G, with Garli v2.0 (51). Statistical support for internal branches was determined by ML-based approximate likelihood ratio test (aLRT) Shimodaira-Hasegawa (SH)-like branch support, as implemented in PhyML 3.0 (52). SH values of  $>0.9$  were considered statistically significant (53). For subtype analysis, our data set was aligned with reference sequences of the major HIV-2 subtypes (downloaded from the Los Alamos Sequence Database [54]) in MEGA5 using the Clustal algorithm (49), followed by phylogenetic analysis.

**Evolutionary rate analysis.** Analyses of HIV-2 evolutionary rates were performed in BEAST v1.7.5 (55) by reconstructing Bayesian rooted and time-measured phylogenetic trees. Unless otherwise stated, all analyses were performed by running a Markov chain Monte Carlo (MCMC) analysis for  $50 \times 10^6$  generations, with sampling performed every 2,500 to 5,000 generations. Convergence was determined by calculation of effective sample sizes (ESS) of  $>100$  and inspection of traces, as assessed in Tracer v1.6 (available from <http://beast.bio.ed.ac.uk/software/tracer/>), following removal of 10% after burn-in. In explorative analyses, we evaluated different models to find the one that best fit our data (see Table S9 at <https://doi.org/10.1128/mbe.0180822.2020>; <https://doi.org/10.1128/mbe.0180822.2020>). For each individual, the nucleotide substitution rates were estimated using two different clock models (strict and uncorrelated lognormal relaxed clocks), two different demographic models (Bayesian skyline plot and constant size), and either partitioned (1st plus 2nd and 3rd) or nonpartitioned codon positions. Nucleotide substitution rates were estimated using the Hasegawa, Kishino, and Yano (HKY) substitution model (56) with gamma-distributed rates. Exploratory analyses were performed by running a single analysis of  $50 \times 10^6$  MCMC generations as described above. All subsequent analysis were performed in duplicate, and the results were combined in LogCombiner v1.7.5 after the removal of 10% after burn-in (55). Phylogenetic trees were visualized in Figtree v1.40 (available from <http://tree.bio.ed.ac.uk/software/figtree/>).

Hierarchical phylogenetic modeling (HPM) with fixed effects, as implemented in BEAST v1.7.5, was used to compare differences in evolutionary rate between progressor groups (55, 57). HPM allows simultaneous analysis of sequence data from multiple individuals. Information of evolutionary parameters is pooled across populations or individuals through hierarchical prior specification, resulting in a shrinkage effect of the variation when data are sparse for study participants. In addition, fixed effects across a group of individuals (in this case, the faster and slower progressor groups) can be included to test and quantify differences between them. Analyses were performed using a strict or uncorrelated lognormal relaxed clock model with a constant population size model as the tree prior. Both nucleotide substitution rates (HKY) and codon substitution rates (determined using the GY94 codon model) were estimated (56, 58). In a region-specific analysis, the data set was partitioned into the *env* V1V2, C2, V3 and C3 regions and the evolutionary rate was estimated for all regions simultaneously by HPM (strict clock, constant size, and GY94 codon model). Evolutionary rates were compared between groups as assessed by Bayes factors (BFs). A BF value of  $>3$  was considered to represent a significant association (59).

**Absolute rates and divergence plots.** The ratio of nonsynonymous and synonymous substitution rates (dN/dS rate ratio) has been widely used as an indicator of selection and molecular adaptation. However, the dN/dS rate ratio cannot be used to detect simultaneous increases or simultaneous decreases in nonsynonymous and synonymous rates (60). To address this issue and to further dissect and explore the molecular adaptation process, the rate of substitution in every branch in a tree can be divided into expected nonsynonymous (E[N]) and expected synonymous (E[S]) substitution rates. These absolute rate estimates reflect the respective contributions of E[N] and E[S] substitution rates to the overall substitution rate for a particular branch (17). These rates are uncorrected for the number of possible nonsynonymous and synonymous alterations (i.e., the number of possible nonsynonymous alterations is higher than the number of possible synonymous alterations). Consequently, direct comparisons between E[N] and E[S] estimates may be difficult to interpret. However, relative differences between, e.g., patient groups in E[N] or E[S] estimates can still be explored. Analyses of E[N] and E[S] and divergence plots were performed as described by Lemey et al. (17). Briefly, 200 random trees from the HPM analysis (the model settings included HPM performed with a relaxed clock, constant population and constant size, and the GY94 codon model [58]) were selected for each individual to determine E[N] and E[S] rates in HyPhy 2.2.0 (61). The accumulated divergence was estimated and plotted over time using the weighted average rate. The analysis was performed using a relaxed clock model because a strict clock model, by definition, would assume a linear relationship.

**Analysis of selected sites.** A Renaissance counting approach, as implemented in BEAST v1.8.1(55), was employed to estimate the ratio of nonsynonymous and synonymous substitutions at each codon site, allowing identification of sites that were under positive or negative selection (62). A dN/dS value of 1 suggests neutral selection, a dN/dS value of  $>1$  suggests positive selection, and a dN/dS value of  $<1$  suggests negative selection. The analysis was performed using a strict clock model with a constant population size model as the tree prior and a triply partitioned (first, second, and third) HKY nucleotide

substitution model (56). Significant positive or negative selection was considered to have occurred when the HPD interval did not include a value of 1.

**HIV-2/SIVsm conservation analysis.** The *env* reference sequences of HIV-2 and SIVsm ( $n = 61$  and  $n = 54$ , respectively) were downloaded from the Los Alamos Database and aligned using the Clustal algorithm. A strict consensus sequence was obtained using Consensus Maker (available at <https://www.hiv.lanl.gov/>). Amino acid positions with 100% amino acid conservation were considered to represent HIV-2/SIVsm conserved positions (see Table S8 at [https://dochub.com/patrik-medstrand/zqp8z8/supplementaryinformation\\_palm\\_mbio\\_ver2\\_180822?dt=Nx2HKD\\_\\_sa\\_SKWC-XzVE](https://dochub.com/patrik-medstrand/zqp8z8/supplementaryinformation_palm_mbio_ver2_180822?dt=Nx2HKD__sa_SKWC-XzVE)).

**Surface accessibility.** The solvent accessibility surface area of the HIV-2 gp125 core (PDB accession number 5CAY) was quantified using the Web server running DSSP (<http://www.cmbi.ru.nl/xssp/>) (63). The relative solvent accessibility (RSA) was calculated as the accessible area divided by the maximum accessible area of the amino acid in extended tripeptide conformation (Gly-X-Gly), as previously described (64). Residues with an RSA value of  $\geq 5\%$  were considered to be surface exposed (65). The HIV-2 Env protein (PDB accession number 5CAY) was visualized and surface exposed, and positively selected amino acids were edited using UCSF Chimera (<https://www.cgl.ucsf.edu/chimera/>).

**Statistical analysis.** Statistical analyses were performed in IBM SPSS Statistics 21 using the two-tailed Mann-Whitney U test (M-W) for continuous variables, the two-tailed Fisher's exact test (FET) for categorical variables, Spearman's rho for correlation analyses, and Friedman's test for comparisons of multiple groups. Results from the Friedman's test showing statistical significance were then analyzed by the Bonferroni-corrected Wilcoxon signed rank test for pairwise comparisons of groups.

**Ethics approval and consent to participate.** The study was approved by the ethics committees of the government of Guinea-Bissau; the University of Lund, Sweden; and the Karolinska Institute, Stockholm. Study participants were counselled and provided informed oral consent.

Supplementary information (including supplementary text, figures, and tables) has been deposited at [https://dochub.com/patrik-medstrand/zqp8z8/supplementaryinformation\\_palm\\_mbio\\_ver2\\_180822?dt=Nx2HKD\\_\\_sa\\_SKWC-XzVE](https://dochub.com/patrik-medstrand/zqp8z8/supplementaryinformation_palm_mbio_ver2_180822?dt=Nx2HKD__sa_SKWC-XzVE).

**Data availability.** The data sets generated and analyzed during the current study are available in the GenBank repository (accession numbers: [KM390990](https://www.ncbi.nlm.nih.gov/nuccore/KM390990) to [KM391398](https://www.ncbi.nlm.nih.gov/nuccore/KM391398)).

## ACKNOWLEDGMENTS

We thank all participants in the study. We also thank Aquilina Sambu, Isabel da Costa, Jacqueline Pereira, Siaca Sambu, and Ana Monteiro Watche at the Health Station of the 2a esquadra, Bissau, and Braima Dabo, Carla Pereira, Julieta Pinto Delgado, Leonvengilda Fernandes Mendes, Ana Monteiro, and Inacio Gomes at the National Public Health Laboratory in Bissau. We also thank Mauno Vihinen for assistance with the Chimera software.

The study was supported by the Department for Research Cooperation (SAREC) at the Swedish International Development Agency (Sida) and the Swedish Research Council (no. 350-2012-6628 and 2016-01417 for J.E.; no. 2016-02285 for M.J.; no. 321-2012-3274 for P.M.). J.E. also acknowledges funding from Swedish Society of Medical Research (SA-2016). P.L. acknowledges funding from the European Union Seventh Framework Program (FP7/2007-2013) under grant agreement no. 260864.

Members of the Sweden Guinea-Bissau Cohort Research (SWEGUB CORE) group include Babetida N'Buna, Antonio Biague, Ansu Biai, Cidia Camara, Joakim Esbjörnsson, Marianne Jansson, Sara Karlson, Jacob Lopatko Lindman, Patrik Medstrand, Fredrik Månsson, Hans Norrgren, Angelica A. Palm, Gülsen Özkaya Sahin, and Zacarias Jose da Silva.

P.M. and J.E. contributed equally to this study. A.A.P., J.E., and P.M. interpreted the data and were responsible for the overall study design. M.J., P.M., and H.N. were responsible for the overall project coordination. F.M., H.N., and A.B. were responsible with respect to the medical and organizational concerns associated with the clinical sites with biological samples of the study participants in the cohort. Z.J.D.S. was responsible for analyses of HIV serology and T-cell count determinations at the laboratory in Guinea-Bissau. F.M. and H.N. coordinated the laboratory and clinical work in Guinea-Bissau and performed database entry and cleaning. A.A.P., J.E., P.M., and Z.S. performed the analyses. A.K., P.L., J.E., and P.M. contributed to the statistical analyses. M.J., S.L.R.-J., and P.L. participated in interpretation of the results. A.A.P., J.E., and P.M. wrote the manuscript. All of us read and approved the manuscript.

We declare that we have no competing financial interests.

## REFERENCES

- Schim van der Loeff MF. 2008. Epidemiology, natural history and treatment of HIV-2 infections, p 637–647. In Volberding PA, Sande MA, Lange J, Greene WC, Gallant J (ed), *Global HIV/AIDS Medicine*. Elsevier, Philadelphia, PA.
- Nyamweya S, Hegedus A, Jaye A, Rowland-Jones S, Flanagan KL, Macallan DC. 2013. Comparing HIV-1 and HIV-2 infection: lessons for viral immunopathogenesis. *Rev Med Virol* 23:221–240. <https://doi.org/10.1002/rmv.1739>.
- Gueudin M, Damond F, Braun J, Taïeb A, Lemée V, Plantier J-C, Chêne G, Matheron S, Brun-Vézinet F, Simon F. 2008. Differences in proviral DNA load between HIV-1- and HIV-2-infected patients. *AIDS* 22:211–215. <https://doi.org/10.1097/QAD.0b013e3282f42429>.
- Blaak H, van der Ende ME, Boers PH, Schuitemaker H, Osterhaus AD. 2006. In vitro replication capacity of HIV-2 variants from long-term aviremic individuals. *Virology* 353:144–154. <https://doi.org/10.1016/j.virol.2006.05.029>.
- MacNeil A, Sankale JL, Meloni ST, Sarr AD, Mboup S, Kanki P. 2007. Long-term inpatient viral evolution during HIV-2 infection. *J Infect Dis* 195:726–733. <https://doi.org/10.1086/511308>.
- Berry N, Ariyoshi K, Jaffar S, Sabally S, Corrah T, Tedder R, Whittle H. 1998. Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection. *J Hum Virol* 1:457–468.
- Popper SJ, Sarr AD, Travers KU, Gueye-Ndiaye A, Mboup S, Essex ME, Kanki PJ. 1999. Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. *J Infect Dis* 180:1116–1121. <https://doi.org/10.1086/315010>.
- Andersson S, Norrgren H, da Silva Z, Biague A, Bamba S, Kwok S, Christopherson C, Biberfeld G, Albert J. 2000. Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection. *Arch Intern Med* 160:3286–3293.
- Rowland-Jones SL, Whittle HC. 2007. Out of Africa: what can we learn from HIV-2 about protective immunity to HIV-1? *Nat Immunol* 8:329–331. <https://doi.org/10.1038/nio407-329>.
- Tchounga B, Ekouevi DK, Balestre E, Dabis F. 2016. Mortality and survival patterns of people living with HIV-2. *Curr Opin HIV AIDS* 11:537–544. <https://doi.org/10.1097/COH.0000000000000299>.
- Esbjornsson J, Mansson F, Kvist A, da Silva ZJ, Andersson S, Fenyo EM, Isberg PE, Biague AJ, Lindman J, Palm AA, Rowland-Jones SL, Jansson M, Medstrand P, Norrgren H, Sweden and Guinea-Bissau Cohort Research Group. 2018. Long-term follow-up of HIV-2-related AIDS and mortality in Guinea-Bissau: a prospective open cohort study. *Lancet HIV* 2018:S2352–3018(18)30254–6. [https://doi.org/10.1016/S2352-3018\(18\)30254-6](https://doi.org/10.1016/S2352-3018(18)30254-6).
- Audige A, Taffe P, Rickenbach M, Battegay M, Vernazza P, Nadal D, Speck RF, Swiss HIVCS. 2010. Low postseroconversion CD4 count and rapid decrease of CD4 density identify HIV+ fast progressors. *AIDS Res Hum Retroviruses* 26:997–1005. <https://doi.org/10.1089/aid.2009.0263>.
- Esbjornsson J, Mansson F, Kvist A, Isberg PE, Biague AJ, da Silva ZJ, Jansson M, Fenyo EM, Norrgren H, Medstrand P. 2014. Increased survival among HIV-1 and HIV-2 dual-infected individuals compared to HIV-1 single-infected individuals. *AIDS* 28:949–957.
- Esbjornsson J, Mansson F, Kvist A, Isberg PE, Nowroozalizadeh S, Biague AJ, da Silva ZJ, Jansson M, Fenyo EM, Norrgren H, Medstrand P. 2012. Inhibition of HIV-1 disease progression by contemporaneous HIV-2 infection. *N Engl J Med* 367:224–232. <https://doi.org/10.1056/NEJMoa1113244>.
- Fahey JL, Taylor JM, Detels R, Hofmann B, Melmed R, Nishanian P, Giorgi JV. 1990. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. *N Engl J Med* 322:166–172. <https://doi.org/10.1056/NEJM199001183220305>.
- Rambaut A, Posada D, Crandall KA, Holmes EC. 2004. The causes and consequences of HIV evolution. *Nat Rev Genet* 5:52–61. <https://doi.org/10.1038/nrg1246>.
- Lemey P, Kosakovsky Pond SL, Drummond AJ, Pybus OG, Shapiro B, Barroso H, Taveira N, Rambaut A. 2007. Synonymous substitution rates predict HIV disease progression as a result of underlying replication dynamics. *PLoS Comput Biol* 3:e29. <https://doi.org/10.1371/journal.pcbi.0030029>.
- Salemi M. 2013. The intra-host evolutionary and population dynamics of human immunodeficiency virus type 1: a phylogenetic perspective. *Infect Dis Rep* 5:e3. <https://doi.org/10.4081/idr.2013.s1.e3>.
- Sankale JL, de la Tour RS, Renjifo B, Siby T, Mboup S, Marlink RG, Essex ME, Kanki PJ. 1995. Inpatient variability of the human immunodeficiency virus type 2 envelope V3 loop. *AIDS Res Hum Retroviruses* 11:617–623.
- Borrego P, Marcelino JM, Rocha C, Doroana M, Antunes F, Maltez F, Gomes P, Novo C, Barroso H, Taveira N. 2008. The role of the humoral immune response in the molecular evolution of the envelope C2, V3 and C3 regions in chronically HIV-2 infected patients. *Retrovirology* 5:78. <https://doi.org/10.1186/1742-4690-5-78>.
- Skar H, Borrego P, Wallstrom TC, Mild M, Marcelino JM, Barroso H, Taveira N, Leitner T, Albert J. 2010. HIV-2 genetic evolution in patients with advanced disease is faster than that in matched HIV-1 patients. *J Virol* 84:7412–7415. <https://doi.org/10.1128/JVI.02548-09>.
- Mansson F, Biague A, da Silva ZJ, Dias F, Nilsson LA, Andersson S, Fenyo EM, Norrgren H. 2009. Prevalence and incidence of HIV-1 and HIV-2 before, during and after a civil war in an occupational cohort in Guinea-Bissau, West Africa. *AIDS* 23:1575–1582. <https://doi.org/10.1097/QAD.0b013e32832cedfb>.
- Norrgren H, Andersson S, Naucler A, Dias F, Johansson I, Biberfeld G. 1995. HIV-1, HIV-2, HTLV-I/II and *Treponema pallidum* infections: incidence, prevalence, and HIV-2-associated mortality in an occupational cohort in Guinea-Bissau. *J Acquir Immune Defic Syndr Hum Retrovirology* 9:422–428. <https://doi.org/10.1097/00042560-199508000-00014>.
- Barroso H, Borrego P, Bartolo I, Marcelino JM, Familia C, Quintas A, Taveira N. 2011. Evolutionary and structural features of the C2, V3 and C3 envelope regions underlying the differences in HIV-1 and HIV-2 biology and infection. *PLoS One* 6:e14548. <https://doi.org/10.1371/journal.pone.0014548>.
- VandeWoude S, Apetrei C. 2006. Going wild: lessons from naturally occurring T-lymphotropic lentiviruses. *Clin Microbiol Rev* 19:728–762. <https://doi.org/10.1128/CMR.00009-06>.
- Davenport YW, West AP, Jr, Bjorkman PJ. 2016. Structure of an HIV-2 gp120 in complex with CD4. *J Virol* 90:2112–2118. <https://doi.org/10.1128/JVI.02678-15>.
- Marcelino JM, Nilsson C, Barroso H, Gomes P, Borrego P, Maltez F, Rosado L, Doroana M, Antunes F, Taveira N. 2008. Envelope-specific antibody response in HIV-2 infection: C2V3C3-specific IgG response is associated with disease progression. *AIDS* 22:2257–2265. <https://doi.org/10.1097/QAD.0b013e3283155546>.
- Jaffar S, Wilkins A, Ngom PT, Sabally S, Corrah T, Bangali JE, Rolfe M, Whittle HC. 1997. Rate of decline of percentage CD4+ cells is faster in HIV-1 than in HIV-2 infection. *J Acquir Immune Defic Syndr Hum Retrovirology* 16:327–332.
- Poulsen AG, Aaby P, Larsen O, Jensen H, Naucler A, Lisse IM, Christiansen CB, Dias F, Melbye M. 1997. 9-Year HIV-2-associated mortality in an urban community in Bissau, West Africa. *Lancet* 349:911–914. [https://doi.org/10.1016/S0140-6736\(96\)04402-9](https://doi.org/10.1016/S0140-6736(96)04402-9).
- van der Loeff MF, Lark N, Kaye S, Berry N, Ariyoshi K, Alabi A, van Tienen C, Leligdowicz A, Sarge-Njie R, da Silva Z, Jaye A, Ricard D, Vincent T, Jones SR, Aaby P, Jaffar S, Whittle H. 2010. Undetectable plasma viral load predicts normal survival in HIV-2-infected people in a West African village. *Retrovirology* 7:46. <https://doi.org/10.1186/1742-4690-7-46>.
- Moir S, Chun TW, Fauci AS. 2011. Pathogenic mechanisms of HIV disease. *Annu Rev Pathol* 6:223–248. <https://doi.org/10.1146/annurev-pathol-011110-130254>.
- Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, Narvaez AB, Hunt P, Martin JN, Kahn JO, Levy J, McGrath MS, Hecht FM. 2004. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. *Blood* 104:942–947. <https://doi.org/10.1182/blood-2003-09-3333>.
- Raboud JM, Haley L, Montaner JS, Murphy C, Januszewska M, Schechter MT. 1995. Quantification of the variation due to laboratory and physiologic sources in CD4 lymphocyte counts of clinically stable HIV-infected individuals. *J Acquir Immune Defic Syndr Hum Retrovirology* 10(Suppl 2):S67–S73.
- Williams BG, Korenromp EL, Gouws E, Dye C. 2009. The rate of decline of CD4 T-cells in people infected with HIV. *arXiv* 0908.1556 [q-bio.CB]. <https://arxiv.org/abs/0908.1556>.
- Berry N, Jaffar S, Schim van der Loeff MF, Ariyoshi K, Harding E, N'Gom PT,

- Dias F, Wilkins A, Ricard D, Aaby P, Tedder R, Whittle H. 2002. Low level viremia and high CD4% predict normal survival in a cohort of HIV type-2-infected villagers. *AIDS Res Hum Retroviruses* 18:1167–1173. <https://doi.org/10.1089/08892220260387904>.
36. Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, Stanfield RL, Dimitrov DS, Korber B, Sodroski J, Wilson IA, Wyatt R, Kwong PD. 2005. Structure of a V3-containing HIV-1 gp120 core. *Science* 310:1025–1028. <https://doi.org/10.1126/science.1118398>.
37. Marcelino JM, Barroso H, Goncalves F, Silva SM, Novo C, Gomes P, Camacho R, Taveira N. 2006. Use of a new dual-antigen enzyme-linked immunosorbent assay to detect and characterize the human antibody response to the human immunodeficiency virus type 2 envelope gp125 and gp36 glycoproteins. *J Clin Microbiol* 44:607–611. <https://doi.org/10.1128/JCM.44.2.607-611.2006>.
38. Huang ML, Essex M, Lee TH. 1991. Localization of immunogenic domains in the human immunodeficiency virus type 2 envelope. *J Virol* 65:5073.
39. Mild M, Gray RR, Kvist A, Lemey P, Goodenow MM, Fenyo EM, Albert J, Salemi M, Esbjornsson J, Medstrand P. 2013. High inpatient HIV-1 evolutionary rate is associated with CCR5-to-CXCR4 coreceptor switch. *Infect Genet Evol* 19:369–377. <https://doi.org/10.1016/j.meegid.2013.05.004>.
40. Popper SJ, Sarr AD, Gueye-Ndiaye A, Mboup S, Essex ME, Kanki PJ. 2000. Low plasma human immunodeficiency virus type 2 viral load is independent of proviral load: low virus production in vivo. *J Virol* 74:1554–1557.
41. Bielejec F, Baele G, Rodrigo AG, Suchard MA, Lemey P. 2016. Identifying predictors of time-inhomogeneous viral evolutionary processes. *Virus Evol* 2:vev023. <https://doi.org/10.1093/ve/vev023>.
42. Barroso H, Taveira N. 2005. Evidence for negative selective pressure in HIV-2 evolution in vivo. *Infect Genet Evol* 5:239–246. <https://doi.org/10.1016/j.meegid.2004.07.008>.
43. Edwards CT, Holmes EC, Pybus OG, Wilson DJ, Viscidi RP, Abrams EJ, Phillips RE, Drummond AJ. 2006. Evolution of the human immunodeficiency virus envelope gene is dominated by purifying selection. *Genetics* 174:1441–1453. <https://doi.org/10.1534/genetics.105.052019>.
44. Ross HA, Rodrigo AG. 2002. Immune-mediated positive selection drives human immunodeficiency virus type 1 molecular variation and predicts disease duration. *J Virol* 76:11715–11720.
45. Leitman EM, Willberg CB, Tsai MH, Chen H, Buus S, Chen F, Riddell L, Haas D, Fellay J, Goedert JJ, Piechocka-Trocha A, Walker BD, Martin J, Deeks S, Wolinsky SM, Martinson J, Martin M, Qi Y, Saez-Cirion A, Yang OO, Matthews PC, Carrington M, Goulder PJR. 2017. HLA-B\*14:02-restricted Env-specific CD8(+) T-cell activity has highly potent antiviral efficacy associated with immune control of HIV infection. *J Virol* 91:e00544-17. <https://doi.org/10.1128/JVI.00544-17>.
46. Bohl C, Bowder D, Thompson J, Abrahamyan L, Gonzalez-Ramirez S, Mao Y, Sodroski J, Wood C, Xiang SH. 2013. A twin-cysteine motif in the V2 region of gp120 is associated with SIV envelope trimer stabilization. *PLoS One* 8:e69406. <https://doi.org/10.1371/journal.pone.0069406>.
47. Hare CB. 2006. WHO staging system for HIV infection and disease in adolescents and adults, table 3; clinical overview of HIV disease. HIV InSite Knowledge Base [textbook online]. UCSF Center for HIV Information, San Francisco, CA.
48. Anonymous. 1999. Guidelines for national human immunodeficiency virus case surveillance, including monitoring for human immunodeficiency virus infection and acquired immunodeficiency syndrome. *Centers for Disease Control and Prevention. MMWR Recomm Rep* 48:1–27, 29–31.
49. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. 2011. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. *Mol Biol Evol* 28:2731–2739. <https://doi.org/10.1093/molbev/msr121>.
50. Bruen TC, Philippe H, Bryant D. 2006. A simple and robust statistical test for detecting the presence of recombination. *Genetics* 172:2665–2681. <https://doi.org/10.1534/genetics.105.048975>.
51. Zwickl DJ. 2006. Genetic algorithm approaches for the phylogenetic analysis of large biological sequence datasets under the maximum likelihood criterion. PhD dissertation. University of Texas at Austin, Austin, TX.
52. Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, Gascuel O. 2010. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. *Syst Biol* 59:307–321. <https://doi.org/10.1093/sysbio/syq010>.
53. Anisimova M, Gil M, Dufayard JF, Dessimoz C, Gascuel O. 2011. Survey of branch support methods demonstrates accuracy, power, and robustness of fast likelihood-based approximation schemes. *Syst Biol* 60:685–699. <https://doi.org/10.1093/sysbio/syr041>.
54. Los Alamos National Laboratory. 2014. HIV sequence database. <http://www.hiv.lanl.gov/>. Accessed October 2014.
55. Drummond AJ, Rambaut A. 2007. BEAST: Bayesian evolutionary analysis by sampling trees. *BMC Evol Biol* 7:214. <https://doi.org/10.1186/1471-2148-7-214>.
56. Hasegawa M, Kishino H, Yano T. 1985. Dating of the human-ape splitting by a molecular clock of mitochondrial DNA. *J Mol Evol* 22:160–174.
57. Edo-Matas D, Lemey P, Tom JA, Serna-Bolea C, van den Blink AE, van 't Wout AB, Schuitemaker H, Suchard MA. 2011. Impact of CCR5delta32 host genetic background and disease progression on HIV-1 intrahost evolutionary processes: efficient hypothesis testing through hierarchical phylogenetic models. *Mol Biol Evol* 28:1605–1616. <https://doi.org/10.1093/molbev/msq326>.
58. Goldman N, Yang Z. 1994. A codon-based model of nucleotide substitution for protein-coding DNA sequences. *Mol Biol Evol* 11:725–736. <https://doi.org/10.1093/oxfordjournals.molbev.a040153>.
59. Kass RE, Raftery AE. 1995. Bayes factors. *J Am Stat Assoc* 90:773–795. <https://doi.org/10.1080/01621459.1995.10476572>.
60. Seo TK, Kishino H, Thorne JL. 2004. Estimating absolute rates of synonymous and nonsynonymous nucleotide substitution in order to characterize natural selection and date species divergences. *Mol Biol Evol* 21:1201–1213. <https://doi.org/10.1093/molbev/msh088>.
61. Pond SL, Frost SD, Muse SV. 2005. HyPhy: hypothesis testing using phylogenies. *Bioinformatics* 21:676–679. <https://doi.org/10.1093/bioinformatics/bti079>.
62. Lemey P, Minin VN, Bielejec F, Kosakovsky Pond SL, Suchard MA. 2012. A counting renaissance: combining stochastic mapping and empirical Bayes to quickly detect amino acid sites under positive selection. *Bioinformatics* 28:3248–3256. <https://doi.org/10.1093/bioinformatics/bts580>.
63. Touw WG, Baakman C, Black J, Te Beek TA, Krieger E, Joosten RP, Vriend G. 2015. A series of PDB-related databanks for everyday needs. *Nucleic Acids Res* 43:D364–D368. <https://doi.org/10.1093/nar/gku1028>.
64. Tien MZ, Meyer AG, Sydykova DK, Spielman SJ, Wilke CO. 2013. Maximum allowed solvent accessibilities of residues in proteins. *PLoS One* 8:e80635. <https://doi.org/10.1371/journal.pone.0080635>.
65. Miller S, Janin J, Lesk AM, Chothia C. 1987. Interior and surface of monomeric proteins. *J Mol Biol* 196:641–656.